STOCK TITAN

Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology firm, announced its participation in the Jefferies Global Healthcare Conference on June 5, 2024. Bill Lundberg, M.D., CEO of Merus, will engage in a fireside chat at 11:00 a.m. ET. The firm, known for developing multispecific antibodies including Biclonics® and Triclonics®, will live webcast the chat on its Investors page, with the recording accessible for a time post-event.

Loading...
Loading translation...

Positive

  • The fireside chat participation at a prestigious event like the Jefferies Global Healthcare Conference signals the company's active engagement with the investment community.
  • Live webcast and archived access provide transparency and easy access to investors.
  • Potential increased visibility and interest in Merus's innovative oncology treatments.

Negative

  • No new financial or clinical data presented in the PR, which may leave investors wanting more substantial updates.
  • time availability of the archived presentation might restrict information access for late viewers.
Argus Session date unavailable
-1.59% session move Open Argus
Details

News Market Reaction – MRUS

The recorded move for MRUS in the trading session of this news was -1.59%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 a.m. ET.

The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, X and LinkedIn.

Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Merus participate in the Jefferies Global Healthcare Conference?

Merus will participate in the Jefferies Global Healthcare Conference on June 5, 2024.

Who will represent Merus at the Jefferies Global Healthcare Conference?

Bill Lundberg, M.D., President and CEO of Merus, will represent the company.

How can I watch Merus's presentation at the Jefferies Global Healthcare Conference?

The presentation will be webcast live on the Investors page of Merus's website.

Will the presentation be available after the Jefferies Global Healthcare Conference?

Yes, the archived presentation will be available for a time on Merus's Investors page.

Keep reading